# Ticagrelor Versus Clopidogrel in Ischemic Stroke

Study · id `cardio:ct-nct05553613` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05553613](<https://clinicaltrials.gov/study/NCT05553613>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05553613

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 900 participants.

## Technical summary

Registry record NCT05553613. Randomized; double masking; primary purpose treatment. Start 2022-10-01 (actual); primary completion 2023-10-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 900 participants (enrolled count; ClinicalTrials.gov record NCT05553613, source copy `cardio:ctgov-nct05553613-2024-05-14`, retrieved 2026-10-26)
- Started: 2022-10-01 (actual) (ClinicalTrials.gov record NCT05553613, source copy `cardio:ctgov-nct05553613-2024-05-14`, retrieved 2026-10-26)
- Primary completion: 2023-10-01 (actual) (ClinicalTrials.gov record NCT05553613, source copy `cardio:ctgov-nct05553613-2024-05-14`, retrieved 2026-10-26)
- Completion: 2024-01-01 (actual) (ClinicalTrials.gov record NCT05553613, source copy `cardio:ctgov-nct05553613-2024-05-14`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT05553613, source copy `cardio:ctgov-nct05553613-2024-05-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05553613-2024-05-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Ticagrelor Versus Clopidogrel in Ischemic Stroke
- Condition: Ischemic Stroke
- Intervention (Drug): Ticagrelor 90 MG Oral Tablet
- Intervention (Drug): Clopidogrel tablet
- Lead sponsor: Kafrelsheikh University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention is a member of this class by a sourced record link: P2Y12 inhibitors (drug class) (`cardio:p2y12-inhibitors`)
- Registry lists this organization as the lead sponsor: Kafrelsheikh University (`cardio:org-kafrelsheikh-university`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: TICA-CLOP STUDY: Ticagrelor Versus Clopidogrel in Acute Moderate and Moderate-to-Severe Ischemic Stroke, a Randomized Controlled Multi-Center Trial (`cardio:pubmed-39520630`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 26e6b539f61a9dddcff6694bf4ce1f1738bcc68a33e8a8fedfb3c2d3adaf6f3c
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
